Controlled substances; Schedule I; provide certain provisions
HB473 updates Georgia’s controlled substances and dangerous drug schedules. In the controlled substances portion, it adds or revises several Schedule I entries, including methyl 2-methyl-AP-237, ethylphenidate, and a tetrahydrothiophene group-related provision, and it removes acetylpsilocin (4-AcO-DMT) from its prior listing by marking it reserved. These changes are aimed at keeping the state’s Schedule I list current with emerging synthetic drugs and related chemical structures.
The bill also substantially expands the state’s “dangerous drug” list in Code Section 16-13-71 by adding a long list of newly identified pharmaceuticals, biologics, gene therapies, vaccines, and other medical products. The additions include treatments for rare diseases, cancer, immune disorders, and other conditions, as well as peanut allergen powder. As a result, these substances become subject to Georgia’s dangerous drug framework, affecting how they are regulated, dispensed, and handled under state law.
HB473 passed both chambers unanimously, with a 170-0 House vote and a 53-0 Senate vote. The voting history suggests broad bipartisan agreement and little visible opposition. No committee transcript was provided, so the available record does not show extended debate or amendments beyond the bill text itself.
The main point of contention, to the extent one can be inferred from the text, is the breadth of the dangerous-drug updates. Because the bill sweeps in many newly approved or specialized therapies, it may raise practical questions for pharmacies, prescribers, manufacturers, and regulators about compliance and classification. However, the unanimous votes indicate that any such concerns did not translate into legislative opposition.
HB473 amends Title 16, Chapter 13 of the Official Code of Georgia Annotated by revising Schedule I controlled substances and expanding the statutory list of dangerous drugs. It changes the legal status of specific synthetic substances and adds numerous modern prescription drugs, biologics, gene therapies, vaccines, and allergen products to the dangerous-drug list, thereby affecting criminal, regulatory, and pharmacy-related treatment of those substances under Georgia law.
The bill appears to have been received very favorably in both chambers. It passed the House 170-0 and the Senate 53-0, indicating unanimous support and no recorded floor opposition. The available record suggests the measure was viewed as a routine update to keep Georgia’s drug schedules aligned with current substances and medical products.
There is no recorded committee debate or floor dissent in the provided materials, so no explicit controversy is documented. The only likely area of concern is the bill’s very broad expansion of the dangerous-drug list, which could create compliance and classification issues for healthcare providers, pharmacists, and manufacturers. Even so, the unanimous votes suggest these concerns were not politically contentious.